Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Efficacy of auranofin as an inhibitor of desmoid progression.

Scientific reports - 13 Jul 2022

Ito Kan, Nishida Yoshihiro, Hamada Shunsuke, Shimizu Koki, Sakai Tomohisa, Ohkawara Bisei, Alman Benjamin A, Enomoto Atsushi, Ikuta Kunihiro, Koike Hiroshi, Zhang Jiarui, Ohno Kinji, Imagama Shiro

Abstract excerpt

Anticancer drugs and molecular targeted therapies are used for refractory desmoid-type fibromatosis (DF), but occasionally cause severe side effects. The purpose of this study was to identify an effective drug with fewer side effects against DF by drug repositioning, and evaluate its efficacy. FDA-approved drugs that inhibit the proliferation of DF cells harboring S45F mutations of CTNNB1 were screened. An...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Caspase 3
Share to beta Catenin

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Desmoid Tumors

Share to Mutation

Source

Open in PubMed Open full text

Identifiers

PMID: 35831372
DOI: 10.1038/s41598-022-15756-9
PMCID: PMC9279441

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Efficacy of auranofin as an inhibitor of desmoid progression.PMID 35831372Read ↗

A high throughput screen identifies Nefopam as targeting cell proliferation in β-catenin driven neoplastic and reactive fibroproliferative disorders.Semantic proximity Read ↗

Anti-tumor Effects of Idarubicin Hydrochloride in Desmoid Tumors.Semantic proximity Read ↗

Activated Signaling Pathways and Targeted Therapies in Desmoid-Type Fibromatosis: A Literature ReviewSemantic proximity Read ↗

Desmoid-Type Fibromatosis: Who, When, and How to Treat.Semantic proximity Read ↗

Biology and Treatment of Aggressive Fibromatosis or Desmoid Tumor.Semantic proximity Read ↗

Immunohistochemical evaluation of potential molecular targets of desmoid-type fibromatosis.Semantic proximity Read ↗

Chlorhexidine Dihydrochloride Shows Anti-tumor Effects in Desmoid Tumors and Colorectal Cancer.Semantic proximity Read ↗

Clinical Activity of the γ-Secretase Inhibitor PF-03084014 in Adults With Desmoid Tumors (Aggressive Fibromatosis).Semantic proximity Read ↗

Clinical results of active surveillance for extra-abdominal desmoid-type fibromatosis.Semantic proximity Read ↗

Optimal therapy for desmoid tumors: current options and challenges for the future.Semantic proximity Read ↗

Immunohistochemical staining with non-phospho β-catenin as a diagnostic and prognostic tool of COX-2 inhibitor therapy for patients with extra-peritoneal desmoid-type fibromatosis.Semantic proximity Read ↗

Molecular pathogenesis of desmoid tumor and the role of γ-secretase inhibitionSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.